Biotechnology & Medical Research

TradingKey - On September 21, US-listed stocks tied to Greenland resources surged in pre-market trading. Greenland Energy (GLND) soared over 220% at one point, Greenland Mines (GRML) rose by nearly 130% at its peak, and Critical Metals (CRML) surged more than 37%. Market attention is refocusing on Greenland's resource development potential, with the sharp rally in related stocks linked to a recent security agreement reached among the United States, Denmark, and Greenland.

TradingKey - On June 25, Eastern Time, Germany's Merck Group announced that it will acquire US life sciences company Bio-Techne (TECH) for $73 per share in an all-cash transaction, representing an enterprise value of approximately $11.3 billion.

TradingKey - British pharmaceutical giant GSK announced on June 9 that it will acquire U.S. biotechnology company Nuvalent (NUVL) for $10.6 billion in an all-cash deal to bolster its lung cancer drug pipeline. This transaction marks GSK's largest acquisition in over a decade and represents the first major strategic move under new CEO Luke Miels.

TradingKey - On Tuesday Eastern Time, the three major U.S. stock index futures rose in pre-market trading as AI chip stocks extended their recovery rally. A temporary cooling of tensions in the Middle East led to a pullback in oil prices, boosting market risk appetite. As of press time, Dow futures

TradingKey - P3 Health Partners is at $12.38 after pulling back from $18.52 post-earnings high. Ascending trendline from $5.91 intact. Q1 net income +$3M vs -$44M prior year. EBITDA $26M. Target $14.16.

TradingKey - P3 Health Partners Q1 2026: EPS +$0.32 vs -$4.85 estimate. Medical margin jumped from $49 to $231 per member. 2026 EBITDA guidance raised to $20–$60M. Lake Street target raised to $14. PIII at $10.